Arimidex Observational: Reason for and Effect of Change From Tamoxifen
Completed
- Conditions
- Breast Cancer
- Registration Number
- NCT00246961
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to analyse the effect on quality of life after 3 months of treatment after changing adjuvant therapy from tamoxifen to Arimidex.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 200
Inclusion Criteria
- Postmenopausal
- Hormone sensitive breast cancer
- Patient uses tamoxifen or has stopped taking tamoxifen less than 7 days ago
Exclusion Criteria
- Visceral metastases
- Patients with signs of progression at the moment of changing therapy
- Patients who have used other endocrine treatments for breast cancer besides tamoxifen
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Research Site
🇳🇱Zutphen, Netherlands
Research SIte
🇳🇱Dordrecht, Netherlands